iwCLL 2023 | Integrating MRD data into treatment decisions in CLL
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, briefly discusses the value of measurable residual disease (MRD) status in predicting the outcomes of patients with chronic lymphocytic leukemia (CLL) treated with time-limited targeted therapies and chemoimmunotherapy (CIT). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So there are multiple studies on chemoimmunotherapy as well as on time-limited targeted combinations such as venetoclax plus obinutuzumab, which have shown that patients are achieving undetectable MRD rates defined as either below the level of 10 to -4, or even deeper below the level of 10 to -6, that the progression free survival outcome of those patients is excellent. However, we also know, on the other hand, that those patients who still have positive or detectable MRD, particularly when they have also more unfavorable karyotype as unmutated IGVH status, suggests that those patients have a rather poor prognosis and, obviously, they relapse very soon...
So there are multiple studies on chemoimmunotherapy as well as on time-limited targeted combinations such as venetoclax plus obinutuzumab, which have shown that patients are achieving undetectable MRD rates defined as either below the level of 10 to -4, or even deeper below the level of 10 to -6, that the progression free survival outcome of those patients is excellent. However, we also know, on the other hand, that those patients who still have positive or detectable MRD, particularly when they have also more unfavorable karyotype as unmutated IGVH status, suggests that those patients have a rather poor prognosis and, obviously, they relapse very soon. So therefore, I think the time has come now that we address the question, should these be patients who require further treatment, either by extension of the treatment or maybe even changing some types of administered drugs, in order to also get undetectable MRD rates in those patients who initially still had detectable rates.
Read more...
